Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 94 entries
Sorted by: Best Match Show Resources per page
The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018.

Journal for immunotherapy of cancer

Ascierto PA, Butterfield LH, Demaria S, Ferris RL, Freeman GJ, Lo RS, Mantovani A, Nathan P, Hamid O, Politi K, Puzanov I.
PMID: 31416487
J Immunother Cancer. 2019 Aug 15;7(1):221. doi: 10.1186/s40425-019-0683-0.

As part of the 2018 Immunotherapy Bridge congress (November 28-29, Naples, Italy), the Great Debate session featured counterpoint views from leading experts on four topical clinical issues in immunotherapy today. These were: the relative importance of adaptive versus innate...

Cite
Ascierto PA, Butterfield LH, Demaria S, et al. The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018. J Immunother Cancer. 2019;7(1):221doi: 10.1186/s40425-019-0683-0.
Ascierto, P. A., Butterfield, L. H., Demaria, S., Ferris, R. L., Freeman, G. J., Lo, R. S., Mantovani, A., Nathan, P., Hamid, O., Politi, K., & Puzanov, I. (2019). The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018. Journal for immunotherapy of cancer, 7(1), 221. https://doi.org/10.1186/s40425-019-0683-0
Ascierto, Paolo A, et al. "The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018." Journal for immunotherapy of cancer vol. 7,1 (2019): 221. doi: https://doi.org/10.1186/s40425-019-0683-0
Ascierto PA, Butterfield LH, Demaria S, Ferris RL, Freeman GJ, Lo RS, Mantovani A, Nathan P, Hamid O, Politi K, Puzanov I. The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018. J Immunother Cancer. 2019 Aug 15;7(1):221. doi: 10.1186/s40425-019-0683-0. PMID: 31416487; PMCID: PMC6696687.
Copy Download .nbib Format: NLM
Diversity and collaboration for effective immunotherapy.

Nature medicine

Palucka K, Banchereau J.
PMID: 27923023
Nat Med. 2016 Dec 06;22(12):1390-1391. doi: 10.1038/nm.4249.

No abstract available.

Cite
Palucka K, Banchereau J. Diversity and collaboration for effective immunotherapy. Nat Med. 2016;22(12):1390-1391doi: 10.1038/nm.4249.
Palucka, K., & Banchereau, J. (2016). Diversity and collaboration for effective immunotherapy. Nature medicine, 22(12), 1390-1391. https://doi.org/10.1038/nm.4249
Palucka, Karolina, and Banchereau, Jacques. "Diversity and collaboration for effective immunotherapy." Nature medicine vol. 22,12 (2016): 1390-1391. doi: https://doi.org/10.1038/nm.4249
Palucka K, Banchereau J. Diversity and collaboration for effective immunotherapy. Nat Med. 2016 Dec 06;22(12):1390-1391. doi: 10.1038/nm.4249. PMID: 27923023.
Copy Download .nbib Format: NLM
The potential for chemotherapy-free strategies in mantle cell lymphoma.

Blood

Martin P, Ruan J, Leonard JP.
PMID: 28899853
Blood. 2017 Oct 26;130(17):1881-1888. doi: 10.1182/blood-2017-05-737510. Epub 2017 Sep 12.

Mantle cell lymphoma (MCL) may be 1 of the few cancers for which multiple chemotherapy and nonchemotherapy regimens are considered as standard. Despite the significant activity of chemotherapy in the first-line setting and beyond, its limitations are reflected in...

Cite
Martin P, Ruan J, Leonard JP. The potential for chemotherapy-free strategies in mantle cell lymphoma. Blood. 2017;130(17):1881-1888doi: 10.1182/blood-2017-05-737510.
Martin, P., Ruan, J., & Leonard, J. P. (2017). The potential for chemotherapy-free strategies in mantle cell lymphoma. Blood, 130(17), 1881-1888. https://doi.org/10.1182/blood-2017-05-737510
Martin, Peter, et al. "The potential for chemotherapy-free strategies in mantle cell lymphoma." Blood vol. 130,17 (2017): 1881-1888. doi: https://doi.org/10.1182/blood-2017-05-737510
Martin P, Ruan J, Leonard JP. The potential for chemotherapy-free strategies in mantle cell lymphoma. Blood. 2017 Oct 26;130(17):1881-1888. doi: 10.1182/blood-2017-05-737510. Epub 2017 Sep 12. PMID: 28899853.
Copy Download .nbib Format: NLM
A case of treatable dementia with Lewy bodies remarkably improved by immunotherapy.

Journal of neuroimmunology

Abe K, Chiba Y.
PMID: 30784774
J Neuroimmunol. 2019 May 15;330:35-37. doi: 10.1016/j.jneuroim.2019.02.003. Epub 2019 Feb 16.

We report a case of probable dementia with Lewy bodies (DLB) with several findings indicating autoimmune encephalitis (e.g. anti-thyroid antibodies in serum and oligoclonal band and anti-N-methyl-d-aspartic acid receptor antibodies in cerebrospinal fluid). The symptoms and the findings of...

Cite
Abe K, Chiba Y. A case of treatable dementia with Lewy bodies remarkably improved by immunotherapy. J Neuroimmunol. 2019;330:35-37doi: 10.1016/j.jneuroim.2019.02.003.
Abe, K., & Chiba, Y. (2019). A case of treatable dementia with Lewy bodies remarkably improved by immunotherapy. Journal of neuroimmunology, 33035-37. https://doi.org/10.1016/j.jneuroim.2019.02.003
Abe, Kie, and Chiba, Yuhei. "A case of treatable dementia with Lewy bodies remarkably improved by immunotherapy." Journal of neuroimmunology vol. 330 (2019): 35-37. doi: https://doi.org/10.1016/j.jneuroim.2019.02.003
Abe K, Chiba Y. A case of treatable dementia with Lewy bodies remarkably improved by immunotherapy. J Neuroimmunol. 2019 May 15;330:35-37. doi: 10.1016/j.jneuroim.2019.02.003. Epub 2019 Feb 16. PMID: 30784774.
Copy Download .nbib Format: NLM
Advances in Melanoma: The Rationale for the Melanoma Nursing Initiative
.

Clinical journal of oncology nursing

Rubin KM.
PMID: 28738056
Clin J Oncol Nurs. 2017 Aug 01;21(4):7-10. doi: 10.1188/17.CJON.S4.7-10.

This article provides an overview of this supplement, outlining the needs assessment process the Melanoma Nursing Initiative (MNI) used to determine the immunotherapy and targeted therapy topics for discussion as well as the process for developing the consensus statements....

Cite
Rubin KM. Advances in Melanoma: The Rationale for the Melanoma Nursing Initiative
. Clin J Oncol Nurs. 2017;21(4):7-10doi: 10.1188/17.CJON.S4.7-10.
Rubin, K. M. (2017). Advances in Melanoma: The Rationale for the Melanoma Nursing Initiative
. Clinical journal of oncology nursing, 21(4), 7-10. https://doi.org/10.1188/17.CJON.S4.7-10
Rubin, Krista M. "Advances in Melanoma: The Rationale for the Melanoma Nursing Initiative
." Clinical journal of oncology nursing vol. 21,4 (2017): 7-10. doi: https://doi.org/10.1188/17.CJON.S4.7-10
Rubin KM. Advances in Melanoma: The Rationale for the Melanoma Nursing Initiative
. Clin J Oncol Nurs. 2017 Aug 01;21(4):7-10. doi: 10.1188/17.CJON.S4.7-10. PMID: 28738056.
Copy Download .nbib Format: NLM
Should we be combining local tumor therapies with immunotherapies as standard?.

Future oncology (London, England)

Baues C, Schlaak M, von Bergwelt-Baildon M, Theurich S.
PMID: 28829189
Future Oncol. 2017 Aug;13(18):1573-1575. doi: 10.2217/fon-2017-0150. Epub 2017 Aug 22.

No abstract available.

Cite
Baues C, Schlaak M, von Bergwelt-Baildon M, et al. Should we be combining local tumor therapies with immunotherapies as standard?. Future Oncol. 2017;13(18):1573-1575doi: 10.2217/fon-2017-0150.
Baues, C., Schlaak, M., von Bergwelt-Baildon, M., & Theurich, S. (2017). Should we be combining local tumor therapies with immunotherapies as standard?. Future oncology (London, England), 13(18), 1573-1575. https://doi.org/10.2217/fon-2017-0150
Baues, Christian, et al. "Should we be combining local tumor therapies with immunotherapies as standard?." Future oncology (London, England) vol. 13,18 (2017): 1573-1575. doi: https://doi.org/10.2217/fon-2017-0150
Baues C, Schlaak M, von Bergwelt-Baildon M, Theurich S. Should we be combining local tumor therapies with immunotherapies as standard?. Future Oncol. 2017 Aug;13(18):1573-1575. doi: 10.2217/fon-2017-0150. Epub 2017 Aug 22. PMID: 28829189.
Copy Download .nbib Format: NLM
Sequential immunotherapy regimens-expect the unexpected.

The Lancet. Oncology

Serra-Bellver P, Valpione S, Lorigan P.
PMID: 27269742
Lancet Oncol. 2016 Jul;17(7):854-855. doi: 10.1016/S1470-2045(16)30198-X. Epub 2016 Jun 04.

No abstract available.

Cite
Serra-Bellver P, Valpione S, Lorigan P. Sequential immunotherapy regimens-expect the unexpected. Lancet Oncol. 2016;17(7):854-855doi: 10.1016/S1470-2045(16)30198-X.
Serra-Bellver, P., Valpione, S., & Lorigan, P. (2016). Sequential immunotherapy regimens-expect the unexpected. The Lancet. Oncology, 17(7), 854-855. https://doi.org/10.1016/S1470-2045(16)30198-X
Serra-Bellver, Patricio, et al. "Sequential immunotherapy regimens-expect the unexpected." The Lancet. Oncology vol. 17,7 (2016): 854-855. doi: https://doi.org/10.1016/S1470-2045(16)30198-X
Serra-Bellver P, Valpione S, Lorigan P. Sequential immunotherapy regimens-expect the unexpected. Lancet Oncol. 2016 Jul;17(7):854-855. doi: 10.1016/S1470-2045(16)30198-X. Epub 2016 Jun 04. PMID: 27269742.
Copy Download .nbib Format: NLM
A tribute to the life and career of Holbrook Kohrt.

Annals of oncology : official journal of the European Society for Medical Oncology

Marabelle A, Houot R.
PMID: 27166293
Ann Oncol. 2016 Jul;27(7):1183-4. doi: 10.1093/annonc/mdw190. Epub 2016 May 10.

No abstract available.

Cite
Marabelle A, Houot R. A tribute to the life and career of Holbrook Kohrt. Ann Oncol. 2016;27(7):1183-4doi: 10.1093/annonc/mdw190.
Marabelle, A., & Houot, R. (2016). A tribute to the life and career of Holbrook Kohrt. Annals of oncology : official journal of the European Society for Medical Oncology, 27(7), 1183-4. https://doi.org/10.1093/annonc/mdw190
Marabelle, A, and Houot, R. "A tribute to the life and career of Holbrook Kohrt." Annals of oncology : official journal of the European Society for Medical Oncology vol. 27,7 (2016): 1183-4. doi: https://doi.org/10.1093/annonc/mdw190
Marabelle A, Houot R. A tribute to the life and career of Holbrook Kohrt. Ann Oncol. 2016 Jul;27(7):1183-4. doi: 10.1093/annonc/mdw190. Epub 2016 May 10. PMID: 27166293.
Copy Download .nbib Format: NLM
Chronic inflammatory demyelinating polyneuropathy and malignancy: A systematic review.

Muscle & nerve

Rajabally YA, Attarian S.
PMID: 29194677
Muscle Nerve. 2018 Jun;57(6):875-883. doi: 10.1002/mus.26028. Epub 2017 Dec 20.

A systematic review of the literature was performed on the association of chronic inflammatory demyelinating polyneuropathy (CIDP) with malignancy. Hematological disorders are the most common association, particulalry non-Hodgkin lymphoma. CIDP frequently precedes the malignancy diagnosis, and there is a...

Cite
Rajabally YA, Attarian S. Chronic inflammatory demyelinating polyneuropathy and malignancy: A systematic review. Muscle Nerve. 2017;57(6):875-883doi: 10.1002/mus.26028.
Rajabally, Y. A., & Attarian, S. (2018). Chronic inflammatory demyelinating polyneuropathy and malignancy: A systematic review. Muscle & nerve, 57(6), 875-883. https://doi.org/10.1002/mus.26028
Rajabally, Yusuf A, and Attarian, Shahram. "Chronic inflammatory demyelinating polyneuropathy and malignancy: A systematic review." Muscle & nerve vol. 57,6 (2018): 875-883. doi: https://doi.org/10.1002/mus.26028
Rajabally YA, Attarian S. Chronic inflammatory demyelinating polyneuropathy and malignancy: A systematic review. Muscle Nerve. 2018 Jun;57(6):875-883. doi: 10.1002/mus.26028. Epub 2017 Dec 20. PMID: 29194677.
Copy Download .nbib Format: NLM
Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy.

Trends in biochemical sciences

Zhang J, Dang F, Ren J, Wei W.
PMID: 30287140
Trends Biochem Sci. 2018 Dec;43(12):1014-1032. doi: 10.1016/j.tibs.2018.09.004. Epub 2018 Oct 01.

PD-L1, frequently expressed in human cancers, engages with PD-1 on immune cells and contributes to cancer immune evasion. As such, antibodies blocking the PD-1/PD-L1 interaction reactivate cytotoxic T cells to eradicate cancer cells. However, a majority of cancer patients...

Cite
Zhang J, Dang F, Ren J, et al. Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy. Trends Biochem Sci. 2018;43(12):1014-1032doi: 10.1016/j.tibs.2018.09.004.
Zhang, J., Dang, F., Ren, J., & Wei, W. (2018). Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy. Trends in biochemical sciences, 43(12), 1014-1032. https://doi.org/10.1016/j.tibs.2018.09.004
Zhang, Jinfang, et al. "Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy." Trends in biochemical sciences vol. 43,12 (2018): 1014-1032. doi: https://doi.org/10.1016/j.tibs.2018.09.004
Zhang J, Dang F, Ren J, Wei W. Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy. Trends Biochem Sci. 2018 Dec;43(12):1014-1032. doi: 10.1016/j.tibs.2018.09.004. Epub 2018 Oct 01. PMID: 30287140; PMCID: PMC6252278.
Copy Download .nbib Format: NLM
Awakening immunity against cancer: a 2017 primer for clinicians.

Chinese journal of cancer

Jain A, Zhang Q, Toh HC.
PMID: 28823251
Chin J Cancer. 2017 Aug 20;36(1):67. doi: 10.1186/s40880-017-0233-4.

Cancer immunotherapy has finally joined the pillars of cancer treatment-surgery, radiation, chemotherapy, hormonal therapy, and targeted therapy-in improving cancer patient lives. In the last 5 years, the development of immune checkpoint inhibitor and T cell therapy, particularly chimeric antigen...

Cite
Jain A, Zhang Q, Toh HC. Awakening immunity against cancer: a 2017 primer for clinicians. Chin J Cancer. 2017;36(1):67doi: 10.1186/s40880-017-0233-4.
Jain, A., Zhang, Q., & Toh, H. C. (2017). Awakening immunity against cancer: a 2017 primer for clinicians. Chinese journal of cancer, 36(1), 67. https://doi.org/10.1186/s40880-017-0233-4
Jain, Amit, et al. "Awakening immunity against cancer: a 2017 primer for clinicians." Chinese journal of cancer vol. 36,1 (2017): 67. doi: https://doi.org/10.1186/s40880-017-0233-4
Jain A, Zhang Q, Toh HC. Awakening immunity against cancer: a 2017 primer for clinicians. Chin J Cancer. 2017 Aug 20;36(1):67. doi: 10.1186/s40880-017-0233-4. PMID: 28823251; PMCID: PMC5563384.
Copy Download .nbib Format: NLM
Too much of a good thing?.

Science (New York, N.Y.)

Kaiser J.
PMID: 29567703
Science. 2018 Mar 23;359(6382):1346-1347. doi: 10.1126/science.359.6382.1346.

No abstract available.

Cite
Kaiser J. Too much of a good thing?. Science. 2018;359(6382):1346-1347doi: 10.1126/science.359.6382.1346.
Kaiser, J. (2018). Too much of a good thing?. Science (New York, N.Y.), 359(6382), 1346-1347. https://doi.org/10.1126/science.359.6382.1346
Kaiser, Jocelyn. "Too much of a good thing?." Science (New York, N.Y.) vol. 359,6382 (2018): 1346-1347. doi: https://doi.org/10.1126/science.359.6382.1346
Kaiser J. Too much of a good thing?. Science. 2018 Mar 23;359(6382):1346-1347. doi: 10.1126/science.359.6382.1346. PMID: 29567703.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 94 entries